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Cyclin Di overexpression related to retinoblastoma
protein expression as a prognostic marker in human
oesophageal squamous cell carcinoma
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Summary The relationship between aberrant expression of cyclin Dl and retinoblastoma (RB) protein and clinicopathological factors was
investigated in 80 patients with oesophageal SCC using immunohistochemical analyses. Heterogeneous staining of cancer cell nuclei with
antibody to cyclin Dl was found in 31.3% of patients (25 out of 80 patients). Nuclear staining of cancer cells with anti-RB antibody was
homogeneous in 10.0% (8 out of 80 patients) and heterogeneous in 58.8% (47 out of 80 patients). Among cases with homogeneous staining
for RB protein, 75% (six out of eight patients) exhibited simultaneous positivity forcyclin Dl (P < 0.05). No significant relationship was found
between cyclin Dl or RB protein expression and various clinicopathological parameters. The prognosis of patients with cyclin Dl-positive
tumours was significantly poorer than that of the other patients (P < 0.01). In addition, when patients with cyclin Dl-positive and -negative
tumours were stratified according to presence or absence of lymph node metastasis and RB status, the cumulative survival rates in the cyclin
Dl-positive groups were significantly lower for patients without lymph node metastasis (P < 0.01) and for patients whose tumours were
positive for RB (P< 0.0001). Thesefindings suggest the possibility thatcyclin D1 positivity is a useful prognostic marker related tolymph node
metastasis and RB protein expression in human oesophageal SCC, in addition to clinicopathological factors.
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Cyclins form a family ofproteins that complex with cyclin-depen-
dent protein kinases (CDKs) to govern key transitions in the cell
cycle. There are at least 11 distinct cyclin genes in the human
genome, which fall into three categories: G,-phase cyclins (C,
D1-3, E, G and H), S-phase cyclins (A and F) and G2/M-phase
cyclins (A and B1-2) (Sherr, 1993; Pines et al, 1994). Cyclins C,
D1-3, and E reach peaks of synthesis and activity during G1 and
appear to regulate the G,-S-phase transition (Hunter et al, 1991;
Cordon-Cardo, 1995). On the other hand, cyclins A and B1-2
reach maximum levels later in the cell cycle, during S-phase and
G2 (Hunter et al, 1991; Pagano et al, 1992; Cordon-Cardo, 1995).
With the discovery of cyclins and cyclin-dependent kinases, it is
now possible to specifically propose that cyclins are proto-onco-
genes (Hunter et al, 1991; Cordon-Cardo et al, 1995). This hypoth-
esis is supported by the discovery of inappropriate expression of
cyclins in many types of tumours. The diverse patterns of redun-
dant expression ofparticularcyclins, including cyclins D, E and A,
in different tumours and cell lines have been reported repeatedly as
they relate to tumorigenesis (Buckley et al, 1993; Jiang et al, 1993;
Cong et al, 1994; Gillett et al, 1994; Keyomarsi et al, 1994; Jares
et al, 1994; McIntosh et al, 1995; Michalides et al, 1995; Furihata
et al, 1996).
Rearrangements and increased expression ofthe cyclin Dl gene
have been observed in parathyroid adenomas (Motokura et al,
Received 17March 1997
Revised 3June 1997
Accepted 25 June 1997
Correspondence to: M Furihata, Kochi Medical School, Department of
Pathology 11, Nankoku, Kochi 783, Japan
1991) and in a subset of B-cell lymphomas (Withers et al, 1991),
and amplification and increased expression ofthis gene have been
reported in oesophageal (Jiang et al, 1993; Tsuruta et al, 1993;
Adelaide et al, 1995; Naitoh et al, 1995; Shinozaki et al, 1996),
head and neck (Jares et al, 1994; Michalides et al, 1995), hepatic
(Zang et al, 1993) and breast cancers (Gillett et al, 1994;
Keyomarsi et al, 1994). Recently, Naitoh et al (1995) reported that
the overall 5-year survival ofpatients with oesophageal SCC with
tumours strongly positive for cyclin Dl was lower than that of
other patients, and Shinozaki et al (1996) have found that the
survival rate ofpatients with amplification ofthe cyclin Dl gene is
significantly lower than that ofpatients without it. Previous studies
of oesophageal SCC have also provided evidence for the clinical
use of the determination of several new biomarkers in the evalua-
tion of this neoplasm (Kitagawa et al, 1991; Furihata et al, 1993;
Shimaya et al, 1993). However, no consensus has been obtained
regarding the role ofbiomarkers in the evaluation ofoesophageal
SCC. On the other hand, lymph node metastasis is clinically the
most useful indicator for predicting outcome in oesophageal SCC
(Kato et al, 1991, 1993; Fahn et al, 1994). However, poor outcome
of patients with early-stage oesophageal SCC has been reported
(Kato et al, 1991; Fahn et al, 1994). Thus, a new evaluation factor
is needed to assess the biological malignancy ofoesophageal SCC.
The kinase activity of the cyclin DI-cdk4 complex is maximal
between the early and middle stages ofthe G, phase (Matsushime
et al, 1994), and it is thought that this kinase phosphorylates and
inactivates the retinoblastoma (RB) protein during G, (Ewen et al,
1993). Underphosphorylated RB protein has been demonstrated to
form complexes with transcription factors including E2F. This
interaction with E2F is supposed to result in repression of the
activity of this positive transcription factor, which is known to
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Figure 1 Cyclin Dl staining patterns in human oesophageal SCC by
immunohistochemistry (bar = 50 gm). (A) Strong staining was limited to the
nuclei of cancer cells revealing heterogeneous intensity. No staining is found
in the stroma adjacent to the carcinoma. (B) Scattered positive cells were
often observed in the parabasal layer of normal mucosa
stimulate the expression of genes required for S-phase control.
Besides the interaction of RB protein phosphorylation by the
cyclin Dl-cdk complex, Muller et al (1994) have demonstrated
that the cell cycle-dependent expression of cyclin Dl in tumour
cell lines required the presence of a functional RB protein.
Based on the above findings, we used immunohistochemical
techniques to examine the expression of cyclin D and RB
proteins in human oesophageal SCC, to test the hypothesis that
cyclin Dl is a useful prognostic marker for this tumour and to
elucidate possible interactions between cyclin DI and RB in
tumour development. The relationships between cyclin Dl and RB
protein expression and various clinicopathological factors were
then determined.
MATERIALS AND METHODS
Patients and tumour samples
Eighty cases of primary human oesophageal SCC consecutively
obtained at oesophagectomy in the Department of Surgery II of
Kochi Medical School between 1982 and 1996 (78 patients) and
the Division of Surgery of Kochi Municipal Central Hospital in
1994 (two patients) were studied. Patients who underwent
oesophagectomy in our school had undergone chemotherapy of
Figure 2 RB staining patterns in human oesophageal SCC by
immunohistochemistry (bar = 50 ,um). (A) Heterogeneous 2+ positive staining
was found in cancer cell nuclei, showing considerable cell-to-cell variation in
its intensity. (B) Homogeneous 3+ positive staining was observed in almost
all of the cancer cell nuclei
oral 150-mg bleomycin (30 mg day-' x 5) but no radiation therapy
before surgery. All patients who underwent oesophagectomy in
Kochi Medical School were followed up and mainly received
chemotherapy when recurrence was detected. Of the patients, 70
(87.5%) were male and ten (12.5%) were female. The mean age
was 62.2 years (range 41-86 years). Clinical staging and
histopathological classification were performed using the TNM
system (Hermanek et al, 1992). Twenty-four (30.0%) patients
were in stage I, 15 (18.75%) in stage IIA, 14 (17.5%) in stage IIB,
21 (26.25%) in stage III and six (7.5%) in stage IV. Tumour speci-
mens were fixed in 10% buffered formalin, processed routinely
and embedded in paraffin. In each case, all available haema-
toxylin- and eosin-stained sections were reviewed, and a represen-
tative block was chosen for further studies.
Immunohistochemistry (IHC) with antibodies to cyclin
Dl and RB protein
Sections (5 gm thick) from archival formalin-fixed paraffin-
embedded tissue were placed on poly-L-lysine-coated slides
(Sigma Chemical, St Louis, MO, USA) for IHC. Cyclin Dl and
RB protein expression was assessed by immunohistochemical
examination using an anti-human cyclin Dl monoclonal antibody
(P2D11Fl1, dilution 1:50, Novocastra, Newcastle, UK) and an
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Table 1 Correlation of cyclin Dl and RB protein expression in human
oesophageal SCC
Cyclin Dl
Positive Negative P-value
(1+, 2+) (-) (Chi-square test)
Positive (3+) 6 2 0.013
RB positive (1+, 2+) 14 33
RB negative (-) 5 20
1+, 5-50% of the tumour cells were positive; 2+, 50-80% of the tumour cells
were positive; 3+, >80% of the tumour cells were positive. 3+ was not
observed in cyclin Dl expression.
Table 2 Summary of multivariate Cox regression analysis with survival as
the end point
Factor P-value
Model 1
Cyclin Dl status 0.007
RB status 0.461
Histological grade 0.844
TNM stage 0.0001
Age 0.115
Sex 0.510
Model 2
Cyclin Dl status 0.010
RB status 0.422
Histological grade 0.229
Lymph nodal status 0.0009
Age 0.526
Sex 0.749
anti-human RB monoclonal antibody (3H3, dilution 1:40, MBL,
Nagoya, Japan). After blocking ofendogenous peroxidase activity,
the sections were treated in 10 mmol citrate buffer (heated at
95 ± 5°C) for 10 min forcyclin Dl staining and in deionized water
(heated at 95 ± 5°C) for 10 min for RB staining in a microwave
oven. The deparaffinized sections were pretreated with normal
goat serum for 30 min and incubated with each antibody at 4°C
overnight. Immunohistochemical staining for cyclin Dl and RB
protein was then performed using the avidin-biotin complex
procedure with a streptavidin-biotin complex peroxidase kit
(Histofine SAB-PO Kit; Nichirei, Tokyo, Japan). The sections
were briefly counterstained with methyl green before mounting.
Sections of known positive cases of oesophageal SCC were
included as controls in each run, and a negative control was
obtained by omitting the primary antibody.
Nuclear staining was considered positive if the chromogen was
detected in at least 5% of all nuclei within a microscopic field.
Scores were ranked as: -, negative; +/-, 0-5% of tumour cells
were positive; 1+, 5-50% oftumour cells were positive; 2+, >50%
of tumour cells were positive (Michallides et al, 1995). A visual
assessment was made of the number of positive tumour cells as a
proportion ofthe total. For RB staining, strong homogeneous posi-
tivity in more than 80% of tumour cells was noted in some cases,
and these were ranked as 3+. Expression ofRB protein in a tumour
was considered to be negative when definitely positive nuclear
staining was observed in immediately adjacent non-neoplastic
cells, but not in the tumour cells themselves.
Statistical analysis
Statistical associations between cyclin Dl and RB immunoreac-
tivity, and these variables and various clinicopathological factors
were determined using the Chi-square test (P < 0.05) for categor-
ical variables. Survival analysis was performed excluding patients
with other causes of death or absolutely non-curative operation,
leaving 68 patients for univariate and multivariate survival
analyses. The cumulative survival rates were calculated using the
Kaplan-Meier method, and the statistical significance of differ-
ences was determined using the log-rank test (P < 0.05) (with time
to death as endpoint). The simultaneous effects of more than one
prognostic factor were estimated using the Cox proportional
hazards model. These statistical analyses were performed with
SPSS statistical software (SPSS, Chicago).
RESULTS
Immunohistochemistry with antibodies to cyclin Dl and
RB protein
In total, 25 of 80 (31.25%) tumours exhibited positive nuclear
staining with cyclin Dl antibody, including five (6.25%) cases of
2+ staining and 20 (25.0%) of 1+ staining (Figure lA). Of the
cases considered to exhibit negative staining, nine exhibited very
weak traces ofnuclear staining (+/-). Focal and weak staining was
often observed in normal mucosa adjacent to cyclin DI-positive or
-negative tumours and was always restricted to the parabasal cell
layer ofnon-cancerous squamous cell epithelium (Figure 1B).
Of the 80 tumours, 55 (68.75%) exhibited positive nuclear
staining with RB antibody, including eight (10.0%) cases of 3+
staining, 34 (42.5%) of 2+ staining and 13 (16.25%) of 1+
staining. Twenty-five (31.25%) tumours were negative for staining
with RB antibody, although adjacent normal epithelia were posi-
tive to some extent. Of the cases considered to exhibit negative
staining, four exhibited very weak traces ofnuclear staining (+/-).
In the 47 cases exhibiting heterogeneous positivity, considerable
cell-to-cell variation in the intensity of staining was observed
(Figure 2A). In the eight cases with homogeneous staining, strong
positive reactions were found in most of the cancer cells (Figure
2B). Non-neoplastic elements, such as normal epithelia, endothe-
lial cells, and germinal centre cells oflymph follicles, were mostly
stained with RB antibody.
Statistical analyses
Table 1 shows the relationship between cyclin Dl and RB protein
expression. Of the cases with homogeneous RB positivity, 75%
(six out of eight) exhibited simultaneous labelling for cyclin Dl
(P = 0.013). No significant relationship was found between cyclin
Dl protein expression and various clinicopathological parameters,
including TNM categories, stage, histological grade, and patient
age and sex, or between RB protein expression and clinicopatho-
logical parameters.
The prognosis of patients with cyclin Dl-positive tumours was
significantly poorer than that of patients with cyclin Dl-negative
tumours (P = 0.003) (Figure 3A). There was no significantcorrela-
tion between RB protein expression and patient prognosis. In order
to determine how cyclin Dl positivity and patient prognosis were
affected by other factors, we analysed it under various stratified
clinicopathological factors and RB status. These factors were
lymph node metastasis and RB status. A significant correlation
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or absolutely non-curative operation were also excluded from this
analysis. Table 2 shows two representations ofmultiple regression
models. Cyclin Dl status, TNM stage and lymph node metastasis
were all associated with a significantly poorer prognosis.
Correlations were found among the various prognostic factors
analysed. When we included TNM stage and lymph node metas-
tasis in the same model, lymph node metastasis was not signifi-
cant. Multivariate analysis demonstrated that cyclin Dl status was
an important factor affecting survival (P < 0.01), along with
histopathological stage (P < 0.0001).
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Figure 3 Cumulative Kaplan-Meier survival curves for patients with
oesophageal SCC divided by cyclin Dl immunopositivity. The patients with
other causes of death or absolutely non-curative operation were excluded.
(A) The curves for all patients (n = 68). A statistical significance was found
between the positive and negative groups (P = 0.003). (B) Curves for
patients without lymph node matastasis (n = 36). There was a statistical
significance between the positive and the negative groups (P = 0.0015).
(C) Curves for patients whose tumours were positive for RB (n = 47). There
was also a statistical significance between the positive and the negative
groups (P < 0.0001)
was observed between cyclin DI immunostaining and poor prog-
nosis for the subset of 36 patients without lymph node metastasis
(P = 0.0015) (Figure 3B), but not for the subset of32 patients with
lymph node metastasis (P = 0.14). Similarly, a significant correla-
tion was observed between cyclin Dl immunostaining and poor
prognosis for the subset of 47 patients whose tumours were RB
positive (P < 0.0001) (Figure 3C), but not for the subset of 21
patients whose tumours were RB negative (P = 0.86). Those
patients whose tumours were both cyclin Dl positive and diffusely
RB positive tended to have a poorer prognosis than those patients
whose tumours were only cyclin Dl positive.
We used a multivariate Cox proportional hazards regression
model to determine the combination of independent factors most
informative for prognosis. The patients with other causes ofdeath
DISCUSSION
We studied the aberrant expression of cyclin Dl and RB proteins
in 80 patients with oesophageal SCC and assessed the relation-
ships between cyclin Dl and RB protein expression and various
clinicopathological features of these patients. Immunohisto-
chemistry using antibodies to cyclin Dl and RB made possible
precise measurement of rates of cyclin Dl and RB expression and
patterns ofexpression in individual tumour cells, and this may be a
suitable method of screening for cyclin Dl and RB abnormalities.
A total of 31.3% (25 out of 80) of the tumour samples exhibited
increased expression of cyclin Dl protein, which was observed
predominantly in the nuclei of cancer cells. These findings show a
fair correlation with the initial studies performed by Jiang et al
(1993) and Tsuruta et al (1993), in which amplification of the
cyclin Dl gene was found in 32.0% and 36.4%, respectively, of
oesophageal SCC. Other studies have reported higher (Adelaide et
al, 1995) or slightly lower (Shinozaki et al, 1996) incidences of
amplification of cyclin Dl in oesophageal SCC. Naitoh et al
(1995) reported 42% (5 out of 12) ofamplification ofthe cyclin Dl
gene and 38.2% (21 out of 55) of overexpression of cyclin Dl
protein. In the majority of tumours examined, including
oesophageal SCC, a clear correlation has been found between the
intensity of staining with cyclin DI antibody and the degree of
DNA amplification (Jiang et al, 1993; Naitoh et al, 1995). Given
the reported incidence of cyclin Dl gene amplification in
oesophageal SCC, our finding of overexpression of cyclin Dl
protein may be related to cyclin Dl gene alteration. On the other
hand, immunohistochemical detection of cyclin Dl in human
breast cancers has identified a subset of carcinomas in which the
cyclin Dl gene is overexpressed in the absence of gene amplifica-
tion (Gillett et al, 1994). Such findings imply that mechanisms
other than DNA amplification or gross rearrangement of the gene
might account for the increased expression ofcyclin Dl.
The present study has shown that evaluation of the expression
of cyclin Dl protein is particularly useful in the search for novel
prognostic markers ofoesophageal SCC. Redundant expression or
amplification of cyclin DI in oesophageal SCC has previously
been reported to be related to tumour prognosis (Naitoh et al,
1995; Shinozaki et al, 1996). Our univariate and multivariate
analyses have also shown that cyclin Dl overexpression in
tumours was significantly correlated with patient prognosis.
Patients with overexpression of cyclin Dl had shorter survival
than those without. In addition, cyclin DI positivity and patient
prognosis was affected by the lymph node metastatic factor. When
patients with cyclin Dl overexpression and negative tumours were
stratified by lymph node metastasis, the cumulative survival rates
in the cyclin DI-positive group were significantly lower for
patients without lymph node metastasis but not for those with
lymph node metastasis. Thus, among these patients without lymph
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node metastasis with fairly good prognosis, patients who require
more intensive clinical treatment can be distinguished on the basis
of cyclin Dl positivity. These findings suggest that demonstration
of cyclin Dl overexpression is a useful prognostic indicator and
can supplement TNM classification.
Normal RB protein exhibits positive nuclear staining on
immunohistochemistry, and it has been established that the finding
of a negative RB protein expression pattern permits fairly good
estimation of frequency of the RB gene mutation (Shew et al,
1989; Xu et al, 1989). Normal RB-positive tumour cells in culture
or in vivo exhibit a cell-by-cell heterogeneous RB staining pattern
with variable proportions of intermingled cells with unstained
nuclei (Xu et al, 1991). In the present study, we found that 47 of55
(85.5%) RB-positive tumours in the present study had consider-
able cell-to-cell variation in staining intensity. However, we also
found that 8 of 55 (14.5%) tumours were RB 2+ positive and
exhibited simultaneous labelling for cyclin Dl. This homogeneous
expression pattern has been noted for many types of tumours but
has been considered as being normal (Geradts et al, 1994;
Lipponen et al, 1995). In contrast, Trudel et al (1992) observed
intense RB positivity or 'overexpression' in some grade 3 (nuclear
grade) breast cancers, but they could not clearly explain the reason
for this and considered this finding paradoxical. On the other
hand, RB protein has been shown to form dysfunctional stable
complexes with adenovirus El A proteins, SV 40 large T antigen
and human papillomavirus E7 oncoprotein (Weinberg, 1991).
Regardless of which mechanisms, these findings suggest that the
homogeneous (2+) RB positivity observed in the present study
may be associated with accumulation of the unscheduled RB
protein related to cyclin Dl overexpression.
How unscheduled overexpression of cyclin D1 participates in
tumour progression remains unclear. In the present study, to deter-
mine how cyclin DI positivity and patient prognosis are affected
by other factors, we analysed various stratified clinicopathological
factors and RB status. When patients with cyclin Dl overexpres-
sion and negative tumours were stratified according to RB status, a
significant correlation was observed between cyclin Dl overex-
pression and poor prognosis for patients whose tumours were RB
positive, but not for patients whose tumours were RB negative.
McIntosh et al (1995) similarly found a significant relationship
between cyclin Dl expression and survival for a subset oftumours
that were positive for RB protein expression, but not for all cases
with breast cancer. Muller et al (1994) demonstrated that the cell
cycle-dependent expression of cyclin Dl required the presence of
a functional RB protein, and Jiang et al (1993) reported that ampli-
fication of the cyclin Dl gene was almost always associated with
persistent expression of the RB protein in human oesophageal
carcinomas. Although we found 5 of 80 cases in which cyclin Dl
overexpression occurred with negative RB expression and statis-
tical significance might not be obtained because of the small
number of RB-negative cases, it appears that cyclin Dl protein
overexpression may be related to tumour progression in the pres-
ence of a normal functional RB protein, which is supposed to be
downstream of cyclin D1 in the cell cycle, even though cancer
cells display 'uncontrolled proliferation'.
Although the molecular basis for positive immunostaining of
cyclin DI remains under investigation, the present findings
suggest that detection of cyclin Dl in oesophageal SCC might
have prognostic significance related to lymph node metastasis and
RB protein expression. These findings enable us to choose a post-
operative follow-up schedule of treatment, including radiation and
chemotherapy. As cyclin Dl and RB can be easily demonstrated
immunohistochemically in formalin-fixed, paraffin-embedded
materials, the degree ofbiological malignancy can be easily evalu-
ated in each patient with oesophageal SCC. More comprehensive
studies involving greater numbers of tumours and including
measurement of DNA and/or RNA levels will be required to
confirm these findings.
ABBREVIATIONS
SCC, squamous cell carcinoma; RB, retinoblastoma; IHC,
immunohistochemistry
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